Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIPENT vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Hairy cell leukemia,Cutaneous T-cell lymphoma
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Primarily metabolized by the liver via deamination by adenosine deaminase (ADA).
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 90-95% bound to serum albumin.
47% bound to plasma proteins (primarily albumin)
Volume of distribution (Vd) is approximately 0.4 L/kg, indicating distribution primarily into extracellular fluid.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Not applicable; Nipent is only administered intravenously with 100% bioavailability via that route. Oral bioavailability is negligible and not clinically relevant.
IV: 100% (only IV route); oral: not approved
Contraindicated if creatinine clearance < 60 m L/min. For Cl Cr 60-90 m L/min: reduce dose to 2.5 mg/m2. Not recommended if Cl Cr < 60 m L/min.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
No specific dose adjustment guidelines for Child-Pugh class A or B. Use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in pediatric patients <18 years. No recommended weight-based dosing.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustments recommended for elderly based on age alone; monitor renal function closely as older patients are more likely to have decreased creatinine clearance.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
WARNING: NIPENT (pentostatin) can cause severe bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Fatal hemorrhagic events and infections have occurred. Use with caution in patients with impaired renal function.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Bone marrow suppression: monitor blood counts regularly,Renal toxicity: assess renal function before and during therapy,Hepatotoxicity: monitor liver function tests,Pulmonary toxicity: observe for signs of pneumonitis,Embryofetal toxicity: advise patients of reproductive potential to use effective contraception,Increased risk of infection: avoid live vaccines
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to pentostatin or any component of the formulation,Severe hepatic impairment,Pregnancy (risk of fetal harm)
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 inhibition. No other significant food interactions are reported.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppression, growth restriction).
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Contraindicated during breastfeeding. M/P ratio unknown; pentostatin is excreted in human milk with potential for serious adverse reactions in nursing infants.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No established safe dose; avoid use in pregnancy. If unavoidable, consider reduced dosing based on increased volume of distribution and renal clearance, but individualize with close monitoring for toxicity.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Administer with aggressive pre-hydration (≥2L NS) and urine alkalinization to prevent nephrotoxicity. Monitor for severe myelosuppression, especially neutropenia. Consider leukapheresis for high-risk patients to prevent tumor lysis syndrome. Dose adjustment required for renal impairment (Cr Cl <60 m L/min).
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Drink at least 2-3 liters of water daily to protect kidneys.,Report any unusual bleeding, bruising, or signs of infection (fever, sore throat) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during and for 6 months after therapy.,Do not receive live vaccines during treatment.,Report any new or worsening shortness of breath or chest pain.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIPENT vs CLOFARABINE, answered by our medical review team.
NIPENT is a Antineoplastic Agent that works by Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIPENT and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIPENT is: 5 mg/m2 intravenously over 20-30 minutes every 3 weeks.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIPENT and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIPENT is classified as Category C. Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppre. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.